*Pseudomonas aeruginosa* is an opportunistic, Gram-negative bacterial pathogen that poses a serious threat in nosocomial infections, particularly in immunocompromised patients, such as burn victims, those undergoing cancer therapy, and HIV-infected individuals.^[@ref1]^ It is also a leading cause of death in cystic fibrosis patients.^[@ref2]^*P. aeruginosa* is highly prone to antibiotic resistance through both intrinsic mechanisms such as restricted cell permeability, antibiotic efflux, and biofilm formation as well as acquired mechanisms such as target mutation and enzymatic drug inactivation *via* horizontal gene transfer.^[@ref3],[@ref4]^ A promising strategy to overcome this growing and challenging resistance problem in *P. aeruginosa* is to target nonvital functions that are associated with pathogenicity, such as the production of virulence factors.^[@ref5],[@ref6]^ Because virulence factors are not directly associated with bacterial viability, antivirulence antibiotics may be less susceptible to the development of drug resistance.^[@ref7],[@ref8]^

The synthesis and secretion of numerous virulence factors in *P. aeruginosa* are controlled by three quorum sensing systems that mediate bacterial cell--cell communication using small-molecule natural products.^[@ref9],[@ref10]^ The LasR- and RhlR-regulated systems use acyl homoserine lactones (AHL) as signaling molecules, while the MvfR (PqsR)-regulated system uses two quinolones, PQS (3,4-dihydroxy-2-heptylquinoline, *Pseudomonas* Quinolone Signal)^[@ref11]^ and its biosynthetic precursor HHQ (2-heptyl-4-hydroxyquinoline).^[@ref12]^ By binding the transcriptional activator MvfR (PqsR), PQS and HHQ induce the expression of a variety of virulence factor genes including their own biosynthetic genes, promote biofilm formation, and interact with the distinct AHL-based quorum sensing systems.^[@ref12]−[@ref18]^ Although both HHQ and PQS bind to and activate MvfR, PQS is 100-fold more potent than HHQ.^[@ref12]^ Inhibition of HHQ and PQS biosynthesis should therefore prevent MvfR activation, and consequently MvfR-dependent gene regulation. Toward this end, we report herein the design, synthesis, and biochemical, cellular, and pharmacological evaluation of small-molecule inhibitors of PqsA, an acyl-CoA synthetase used in quinolone biosynthesis. Using rational design based on enzyme mechanism, we have developed potent inhibitors of PqsA that block quinolone biosynthesis in *P. aeruginosa*.

Results and Discussion {#sec2}
======================

Design and Synthesis of PqsA Inhibitors {#sec2.1}
---------------------------------------

Biosynthesis of the quinolone HHQ is thought to involve PqsA--E, with final conversion to PQS involving oxidation by PqsH ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref19],[@ref20]^ Inhibitors of the cyclase PqsD^[@ref22]−[@ref29]^ and the thioesterase activity of PqsE,^[@ref30]^ direct antagonists of the MvfR receptor,^[@ref31]−[@ref37]^ a dual inhibitor of PqsD and MvfR,^[@ref38]^ as well as an inhibitor of the upstream enzyme KynU, which is one source of the anthranilic acid precursor,^[@ref39]^ have been reported. Our efforts to target this pathway have focused on PqsA, an acyl-CoA synthetase (ligase) that catalyzes a key step in quinolone biosynthesis.^[@ref21]^ PqsA converts anthranilic acid to anthranilyl-CoA *via* a two step process involving initial ATP-dependent adenylation of anthranilic acid to form a tightly bound anthranilyl-AMP intermediate, followed by thioesterification with CoA to form anthranilyl-CoA. PqsA has been validated previously as a promising therapeutic target using both genetic and pharmacological approaches. *pqsA*^--^ mutants do not produce HHQ or PQS^[@ref15],[@ref40]^ and are poor biofilm producers *in vitro*.^[@ref41]^ They also exhibit attenuated virulence in a mouse burn infection model,^[@ref16],[@ref42]^ reduced dissemination in a mouse lung infection model,^[@ref40]^ and less biofilm formation and increased susceptibility to clearance by ciprofloxacin in a mouse tumor infection model.^[@ref43]^ There is no known human orthologue of PqsA, although related aliphatic acyl-CoA synthetases are used in metabolism. Thus, selective PqsA inhibitors would not be expected to impact host cell viability. Moreover, haloanthranilate substrate analogues that act as either PqsA substrates or inhibitors have been shown to inhibit PQS production in cell culture^[@ref21]^ and to decrease both quinolone production and mortality in the mouse burn model.^[@ref42]^

![Biosynthesis of the *P. aeruginosa* quinolone quorum sensing factors HHQ and PQS is initiated by PqsA, an anthranilyl-CoA synthetase that first activates anthranilic acid to form a tightly bound anthranilyl-AMP reaction intermediate and then catalyzes thioesterification with CoA to form anthranilyl-CoA.](cb-2016-00575v_0001){#fig1}

Acyl-CoA synthetases belong to a superfamily of structurally and mechanistically related adenylate-forming enzymes that also includes nonribosomal peptide synthetase (NRPS) adenylation domains and firefly luciferase.^[@ref44]^ We^[@ref45]−[@ref53]^ and others^[@ref54]−[@ref66]^ have used 5′-*O*-(*N*-acylsulfamoyl)adenosines (acyl-AMS) and related compounds to inhibit such enzymes by mimicking the cognate, tightly bound acyl-AMP intermediates. Ishida and co-workers first applied this inhibitor design strategy to mechanistically related aminoacyl-tRNA synthetases^[@ref67]^ and were inspired by the sulfamoyladenosine class of natural products that includes nucleocidin and ascamycin.^[@ref68]−[@ref70]^ We envisioned that anthranilyl-AMS (**1**, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) or its sulfamide analogue, anthranilyl-AMSN (**2**), might be effective inhibitors of PqsA and quinolone biosynthesis. The close structural analogues salicyl-AMS (**3**),^[@ref45]^ salicyl-AMSN (**4**),^[@ref59]^ and benzoyl-AMS (**5**)^[@ref59]^ would provide preliminary structure--activity relationship data. We also envisioned that the corresponding vinyl sulfonamides anthranilyl-AVSN (**6**) and salicyl-AVSN (**7**) could inhibit PqsA through covalent binding to the incoming CoA thiol nucleophile during the second half-reaction, forming a mimic of the tetrahedral intermediate.^[@ref71]^ This vinyl sulfonamide inhibitor design strategy was previously used by Aldrich and co-workers to target the NRPS salicylate adenylation domain MbtA,^[@ref71]^ which is involved in bacterial siderophore biosynthesis, and we have also successfully applied this strategy to an acyl-CoA synthetase MenE, which is involved in bacterial menaquinone biosynthesis,^[@ref48],[@ref49]^ as well as E1 activating enzymes involved in conjugation of ubiquitin and ubiquitin-like modifier proteins.^[@ref52],[@ref53]^

###### Inhibition of PqsA by Designed Sulfonyladenosine Inhibitors[a](#t1fn1){ref-type="table-fn"}

![](cb-2016-00575v_0005){#fx1}

  inhibitor                  R       X    *K*~i~^app^ (nM)[b](#t1fn2){ref-type="table-fn"}
  -------------------------- ------- ---- --------------------------------------------------
  anthranilyl-AMS (**1**)    NH~2~   O    205 ± 4.0[c](#t1fn3){ref-type="table-fn"}
  anthranilyl-AMSN (**2**)   NH~2~   NH   170 ± 20[c](#t1fn3){ref-type="table-fn"}
  salicyl-AMS (**3**)        OH      O    88 ± 12
  salicyl-AMSN (**4**)       OH      NH   109 ± 18
  benzoyl-AMS (**5**)        H       O    420 ± 69
  anthranilyl-AVSN (**6**)   NH~2~        36300 ± 4300
  salicyl-AVSN (**7**)       OH           15400 ± 1700

Assays were performed with 60 nM PqsA.

Calculated based on Dixon plots.

Competitive inhibitor with respect to ATP (*K*~i~ = 16.5 ± 2.6 nM, calculated based on Morrison equation) and uncompetitive with respect to anthranilate and CoA.

The acyl-AMS sulfamate (**1**, **3**, **5**) and acyl-AMSN sulfamide (**2**, **4**) inhibitors were readily synthesized by acylation of a protected sulfamoyladenosine or corresponding sulfamide, respectively, followed by global deprotection using aqueous TFA (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acschembio.6b00575/suppl_file/cb6b00575_si_001.pdf) for full details). The sulfamidoadenosine precursor was prepared conveniently by Mitsunobu substitution of the 5′-alcohol of 2′,3′-acetonide-protected adenosine with mono-*N*-Boc-sulfamide. The acyl-AVSN vinyl sulfonamides (**6**, **7**) were synthesized by Mitsunobu substitution with the corresponding *N*-Boc-arylvinylsulfonamides directly, followed by deprotection.^[@ref72]^

Inhibition of PqsA by Anthranilyl-AMP Analogues {#sec2.2}
-----------------------------------------------

With these inhibitors in hand, we evaluated their ability to inhibit PqsA using a quantitative spectrophotometric assay with recombinant PqsA, detecting formation of anthranilyl-CoA at 365 nm.^[@ref21]^ Both anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) were potent inhibitors of PqsA, with *K*~i~^ATP^ values of 205 and 170 nM, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Further analysis of these "tight-binding inhibitors" using the Morrison equation^[@ref73],[@ref74]^ indicated that both anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) are competitive inhibitors with respect to ATP (*K*~i~ = 16.5 ± 2.6 nM; 10.5 ± 2.3 nM, respectively) and uncompetitive inhibitors with respect to anthranilate and CoA.

Interestingly, both salicyl-AMS (**3**) and salicyl-AMSN (**4**) exhibited potency similar to that of the cognate anthranilyl inhibitors, indicating that an *o*-phenolic moiety is tolerated by PqsA. This is generally consistent with the previous finding that salicylate, while not accepted as a substrate, does inhibit PqsA.^[@ref21]^ Benzoyl-AMS (**5**) was a somewhat weaker inhibitor, indicating the importance of an *ortho* substituent on the aromatic ring. This is again consistent with previous biochemical studies indicating that benzoate, while accepted as a PqsA substrate, exhibits a much weaker *K*~m~ compared to anthranilate (150 μM vs 8 μM).^[@ref21]^ In contrast, the corresponding vinyl sulfonamide analogues **6** and **7** were relatively poor inhibitors, at least on the short time scale of this assay. This is consistent with previous studies within this structural superfamily of enzymes, in which we have shown that related vinyl sulfonamides are effective but slow-binding inhibitors of another acyl-CoA synthetase MenE when assayed in the presence of CoA,^[@ref48],[@ref49]^ while Aldrich *et al.* have reported that salicyl-AVSN (**7**) is a weak inhibitor of the salicylate adenylation enzyme MbtA in the absence of the corresponding thiol nucleophile MbtB.^[@ref71]^

Inhibition of *P. aeruginosa* Quinolone Production by Anthranilyl-AMP Analgoues {#sec2.3}
-------------------------------------------------------------------------------

Next, we evaluated the five most potent PqsA inhibitors **1**--**5** for their ability to inhibit HHQ and PQS quinolone production in *P. aeruginosa* strain PA14 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). HHQ and PQS concentrations were determined by LC-MS/MS quantitation^[@ref75]^ relative to deuterated internal standards (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acschembio.6b00575/suppl_file/cb6b00575_si_001.pdf) for full details). The vinyl sulfonamide analogues **6** and **7** were excluded due to their lack of biochemical potency. 6-Fluoroanthranilate (6FABA), a substrate analogue reported previously to inhibit quinolone production at millimolar concentrations,^[@ref42]^ was used as a positive control. Compounds were initially tested at 1.5 mM concentration, and HHQ and PQS were quantified at 8 and 20 h, respectively. These time points were selected based on an initial time course study of quinolone production in the absence of inhibitors, with HHQ or PQS production peaking at these respective time points. The parent inhibitor anthranilyl-AMS (**1**) exhibited good inhibition of both HHQ and PQS production under these conditions (67% and 77% inhibition, respectively), whereas the sulfamide analogue anthranilyl-AMSN (**2**) was more potent (90% and 92% inhibition, respectively), consistent with its increased biochemical potency against PqsA. In contrast, salicyl-AMS (**3**), salicyl-AMSN (**4**), and benzoyl-AMS (**5**) were much less potent inhibitors of quinolone production, despite their similar biochemical potencies against PqsA. This could be due to differences in cell penetration, stability, and/or target specificity. Finally, because inhibitors of the quinolone quorum sensing pathway should not impact bacterial growth, we confirmed that none of the six inhibitors above inhibited growth over 20 h (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acschembio.6b00575/suppl_file/cb6b00575_si_001.pdf) Figure S1).

![Inhibition of HHQ (8 h) and PQS (20 h) quinolone production in *P. aeruginosa* strain PA14 (1.5 mM inhibitors). Statistical significance relative to the blank was assessed using a two-tailed unpaired Student *t*-test with 95% confidence intervals; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001.](cb-2016-00575v_0002){#fig2}

Encouraged by the ability of anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) to inhibit HHQ and PQS quinolone production, we investigated the activity of these two inhibitors and 6FABA in greater detail. In untreated controls, HHQ and PQS production peaked at 8 and 20 h, respectively. Previously reported time course studies have similarly shown that HHQ levels peak at 6--8 h while PQS levels continue to rise.^[@ref15],[@ref76]^ All three inhibitors were able to decrease quinolone production in a dose- and time-dependent manner ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). While none of the inhibitors blocked quinolone production completely at any of the concentrations tested, both anthranilyl-AMSN (**2**) and 6FABA were able to inhibit or delay quinolone production at concentrations as low as 100 μM. Such a perturbation might still be sufficient to impact *P. aeruginosa* virulence *in vivo*. Indeed, 6FABA and related haloanthranilate substrate analogues have been shown to increase survival significantly in a mouse burn infection model, despite the fact that they only reduce HHQ levels partially compared to untreated controls in tissue directly underlying the infection site.^[@ref42]^ Anthranilyl-AMS (**1**) exhibited the same trend of inhibition, albeit again with lower potency.

![Dose- and time-dependent inhibition of HHQ (top) and PQS (bottom) quinolone production in *P. aeruginosa* strain PA14 over 24 h.](cb-2016-00575v_0003){#fig3}

Effect of Anthranilyl-AMP Analogues on *P. aeruginosa* Pyocyanin Production {#sec2.4}
---------------------------------------------------------------------------

We next investigated the ability of these PqsA inhibitors to block production of the virulence factor pyocyanin. Although both anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) were able to reduce HHQ and PQS production at 1 mM concentration (**1**, 47 and 40% inhibition, respectively; **2**, 84% and 84% inhibition, respectively; [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), neither inhibited pyocyanin production at this concentration (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acschembio.6b00575/suppl_file/cb6b00575_si_001.pdf) Figure S2). Of note, MvfR antagonists^[@ref37]^ and PqsD inhibitors^[@ref25],[@ref38]^ that similarly inhibit quinolone production but not pyocyanin production have been reported previously. Haloanthranilate substrate analogues have been reported to inhibit both quinolone and pyocyanin production but may impact multiple targets in this complex signaling network.^[@ref42]^ This is indicative of the complex relationship between HHQ and PQS quinolone biosynthesis, induction of the MvfR regulon, and production of pyocyanin.

Compound Accumulation of Anthranilyl-AMP Analogues in *P. aeruginosa* {#sec2.5}
---------------------------------------------------------------------

It is well-known that *P. aeruginosa* has high intrinsic resistance to small-molecule antibiotics due to limited membrane permeability and high efflux.^[@ref3],[@ref4]^ We hypothesized that this may be the basis for the difference between the potent biochemical activity of our PqsA inhibitors and their modest cellular potencies in *P. aeruginosa*. Thus, we carried out compound accumulation studies with anthranilyl-AMS (**1**), anthranilyl-AMSN (**2**), and 6FABA in *P. aeruginosa* PA14 using an LC-MS/MS quantitation approach (see [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).^[@ref77]^ Cells were grown in LB to early log phase (OD~600~ ≈ 0.5), treated with 1000 μM compound for 30 min, then centrifuged and rapidly washed four times with cold PBS to remove surface-associated compound. The cells were lysed by multiple freeze--thaw cycles, centrifuged, and precipitated with methanol containing an internal standard (benzoyl-AMS, **5**). Compound concentration in the lysate was quantitated by LC-MS/MS relative to the internal standard and the intracellular concentration was calculated based on CFU determination of the culture just prior to washing. Anthranilyl-AMS (**1**), anthranilyl-AMSN (**2**), and 6FABA accumulated to 20--30 μM intracellular concentration under these conditions, corresponding to 2--3% penetration relative to the 1000 μM extracellular concentration applied. These results suggest that limited penetration of anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) into *P. aeruginosa* contributes to the differences between their biochemical and cellular potencies observed above, although other factors such as metabolic stability and/or off-target binding must also be considered. These integrated data provide a basis to correlate biochemical inhibition, bacterial compound accumulation, and cellular activity and indicate that membrane penetration and/or efflux evasion are keys to improving the cellular activity of these rationally designed PqsA inhibitors.

![Compound accumulation in *P. aeruginosa* strain PA14 after incubation with 1000 μM extracellular concentration for 30 min.](cb-2016-00575v_0004){#fig4}

Conclusions {#sec3}
-----------

The *P. aeruginosa* quinolone signaling system is an attractive target for the development of novel therapeutics that block virulence factor production. We have developed a series of rationally designed inhibitors of the anthranilyl-CoA synthetase PqsA, which catalyzes a key step in *P. aeruginosa* quinolone biosynthesis. Anthranilyl-AMS (**1**) and anthranilyl-AMSN (**2**) were identified as potent biochemical inhibitors of PqsA having moderate inhibitory activity against HHQ and PQS quinolone production in *P. aeruginosa*. Compound accumulation studies suggest that the limited cell penetration of these inhibitors may contribute to this difference in biochemical versus cellular activities. This work provides direct pharmacological validation of PqsA as a promising target to inhibit HHQ and PQS quinolone biosynthesis in *P. aeruginosa*. Future efforts will focus on developing analogues with improved cell penetrance or combinations with efflux pump inhibitors or membrane-permeablizing antibiotics to provide more potent cellular activity. These inhibitors will then be useful probes for investigating the interplay between quinolone signaling and virulence factor production in *P. aeruginosa*, including quantitative assessment of the level and timing of virulence factor inhibition required to impact *in vivo* virulence, as well as evaluation in conjunction with other antibiotics, particularly those targeting the interconnected LasR- and RhlR-regulated quorum sensing systems,^[@ref78]^ with the long-term goal of developing novel antivirulence strategies to treat *P. aeruginosa* infections.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acschembio.6b00575](http://pubs.acs.org/doi/abs/10.1021/acschembio.6b00575).Complete experimental procedures and analytical data for all new compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acschembio.6b00575/suppl_file/cb6b00575_si_001.pdf))
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